On August 18, 2021 Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni"), an Australia-based diversified biopharmaceutical enterprise, reported that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr Reddy’s Laboratories Limited (NYSE: RDY; BSE: 500124) (Press release, Beroni Group, AUG 18, 2021, View Source [SID1234597999]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed. In a second clinical trial to commence H1 2022, PENAO is planned to be administered as twice-weekly injections to patients with advanced solid tumors. It is going to be a dose-finding study that also investigates anti-tumor effects using morphological assessments including radiological responses, molecular imaging surrogates, and anti-proliferative effects.
PENAO enjoys the support of a multi-national, high-quality management team including the drug’s co-creator Professor Phil Hogg, and minority shareholder the University of New South Wales, Sydney.
"I am pleased that we are making significant progress in the development of the anti-cancer drug PENAO. PENAO is a novel therapy targeting tumor cell mitochondria and could potentially have application in a wide range of cancers, including colorectal cancer, pancreatic cancer, ovarian cancer, liver cancer, etc.," said Jacky Zhang, CEO of Beroni Group. "It is a potential treatment for cancers that are unresponsive to standard treatment, or for which no standard treatment exists."